Medacta Group Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 3/6
Medacta Group verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 14%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 10.6%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 13%. Die Eigenkapitalrendite von Medacta Group beträgt 14.4% und die Nettomargen betragen 9.3%.
Wichtige Informationen
18.1%
Wachstumsrate der Gewinne
20.5%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | 11.1% |
| Wachstumsrate der Einnahmen | 14.0% |
| Eigenkapitalrendite | 16.3% |
| Netto-Marge | 10.3% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Aufschlüsselung der Einnahmen und Ausgaben
Wie Medacta Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 544 | 56 | 271 | 20 |
| 31 Mar 24 | 528 | 52 | 262 | 19 |
| 31 Dec 23 | 511 | 47 | 252 | 19 |
| 30 Sep 23 | 496 | 49 | 245 | 17 |
| 30 Jun 23 | 481 | 50 | 237 | 17 |
| 31 Mar 23 | 459 | 48 | 228 | 16 |
| 31 Dec 22 | 437 | 46 | 220 | 15 |
| 30 Sep 22 | 417 | 47 | 212 | 14 |
| 30 Jun 22 | 397 | 47 | 203 | 14 |
| 31 Mar 22 | 380 | 49 | 193 | 12 |
| 31 Dec 21 | 363 | 52 | 182 | 11 |
| 30 Sep 21 | 354 | 54 | 173 | 10 |
| 30 Jun 21 | 345 | 57 | 164 | 8 |
| 31 Mar 21 | 324 | 47 | 160 | 7 |
| 31 Dec 20 | 302 | 37 | 155 | 7 |
| 30 Sep 20 | 298 | 24 | 166 | 7 |
| 30 Jun 20 | 294 | 10 | 177 | 7 |
| 31 Mar 20 | 302 | 11 | 177 | 8 |
| 31 Dec 19 | 311 | 12 | 176 | 8 |
| 30 Sep 19 | 301 | 22 | 162 | 6 |
| 30 Jun 19 | 291 | 33 | 147 | 5 |
| 31 Mar 19 | 282 | 39 | 143 | 5 |
| 31 Dec 18 | 273 | 46 | 139 | 4 |
| 31 Dec 17 | 245 | 33 | 129 | 3 |
| 31 Dec 16 | 219 | 39 | 113 | 3 |
Qualität der Erträge: MOVE hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: MOVEDie aktuellen Gewinnspannen (9.3%) sind niedriger als im letzten Jahr (10.6%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: MOVEIn den letzten 5 Jahren sind die Gewinne von 14% jährlich gestiegen.
Beschleunigtes Wachstum: MOVEDas Gewinnwachstum des Unternehmens im letzten Jahr (2.4%) liegt unter seinem 5-Jahres-Durchschnitt (14% pro Jahr).
Erträge im Vergleich zur Industrie: MOVE Das Gewinnwachstum im vergangenen Jahr (2.4%) übertraf das der Branche Medical Equipment -2.4% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: MOVEDie Eigenkapitalrendite des Unternehmens (14.4%) wird als niedrig angesehen.